RxDoctor Payments Data

Marvin Hall, MD

Ophthalmology · Marshall, TXNPI 1104932367

Payments from drug & device makers

$1,867in general payments, 2019–2025

Across 66 payments — averaging $28.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$562
  • AbbVie$521
  • Oyster Point Pharma, Inc.$147
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$142
  • Rayner Intraocular Lenses Limited$125
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$123
  • plus $247 from 7 others

What the payments were for

  • Food & beverage$1,867100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,867 in reported general payments places this provider in the 45th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$210,497
Medicare patients
688
Services billed
1,860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine62$48,964
LumiganBimatoprost74$28,264
XiidraLifitegrast28$23,907
VyzultaLatanoprostene Bunod55$19,463
Prednisolone Acetate316$16,475
CombiganBrimonidine Tartrate/Timolol43$13,203
Alphagan PBrimonidine Tartrate26$11,177
RhopressaNetarsudil Mesylate24$10,352
Cyclosporine40$9,494
Latanoprost1,008$6,814
ProlensaBromfenac Sodium19$6,629
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol46$5,958
Brimonidine Tartrate272$5,698
Travoprost54$5,361
RocklatanNetarsudil Mesylat/Latanoprost16$5,351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$521$101,609205 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$33$43,37083 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$28$15,70340 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Loteprednol Etabonate$142$12,94455 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Marshall

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →